Novavax Inc. (NVAX), a pharmaceutical firm, could have three commercially promising vaccines in its pipeline within a year, including the COVID-19 vaccine.
In terms of producing a coronavirus vaccine, Novavax is marginally behind its rivals, but there is a strong degree of unrealized interest on the global market for such a vaccine. This means that, even though the Novavax vaccine comes out a few months later than its rivals, millions of orders will still be secured. The business is one of the leading competitors in the vaccine race at present and is among 13 programs in clinical phase III trials.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
At the beginning of the first quarter, the organization expects to collect interim results, and the vaccine itself will be available in the first half of the year. Novavax currently has a contract to supply different nations, including the United States, with 286 million doses. The precise price of the company’s COVID-19 vaccine is unclear, but with 100 million doses of the vaccine, the U.S. government has given Novavax $1.6 billion, so one vaccine costs $16 per dose.
If we use this price as a basis, the company’s number of current orders will pull in revenues of $4.5 billion. If Novavax is able to expand manufacturing volume to 2 billion doses by mid-year, future sales may be projected to hit $32 billion.
The NanoFlu flu vaccine, which is in phase III trials, is another promising result of Novavax. The vaccine has met the main safety endpoints, according to the company, and is not inferior to major competitors in immune response. Novavax recently formed a team to perform NanoFlu through the regulatory authorities’ approval process. The company may start selling the vaccine no later than 2022 if the process goes forward without delay.
Novavax has also made progress in developing a vaccine, a hybrid influenza and coronavirus vaccine that does not have competitors on the market yet. If the organization may get authorization from authorities, then the testing of such a vaccine can take place in an accelerated pace.
Thus, Novavax could have a coronavirus vaccine on the market in one year, a ready-to-market influenza vaccine, and a combination of influenza and coronavirus vaccine in the final stages of testing. A breakthrough could be the next advance and carry Novavax billions of dollars in revenues in the long term. Many experts claim that the coronavirus outbreak, as it happens with the flu, will persist for a long time and will need regular vaccination. The combination vaccine may, thus, become the preferred option in many countries’ health systems.
Novavax, Inc. (NVAX) started the year with a rise of +1.32% on Monday to close at $112.98.